Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

Summary

Current anti-diabetic treatment fails to stop the progressive course of the disease. Recent studies have revealed a surprisingly high variability in the diabetic phenotype. The investigators propose that anti-diabetic treatment should ideally target the underlying pathophysiology of each individual patient. The investigators will therefore test whether the effect of two approved anti-diabetic drugs differs between individuals at different ends of the pathophysiological spectrum: 1) patients with poor insulin secretion, here termed SIDD and 2) patients with high insulin resistance, here termed SIRD. The study may open up a new avenue for more precise treatment of diabetic patients that would be of immediate clinical relevance.

Timeline

Start

2020-09-10

Primary completion

2021-12-15

Completion

2026-12-31

Publications

• Dwibedi C, Ekstrom O, Brandt J, Adiels M, Franzen S, Abrahamsson B, Rosengren AH. Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nat Metab. 2024 Jan;6(1):50-60. doi: 10.1038/s42255-023-00943-3. Epub 2024 Jan 4.

Drugs

Indications